Skip to content
To the full analysis

BioMarin Pharmaceutical stock: balance sheet and debt

BMRN
$56.70Closing price of 12 Nov 2026MEQIRI Score 48 out of 100

BioMarin Pharmaceutical has a debt to equity ratio of 0.11 and an interest coverage of 45.3x.

Daily figure as of 13 Nov 2026

Debt / Equity
0.11
Interest coverage
45.3x
Current ratio
5.21
Cash & equivalents
$1.56B
Total assets
$7.59B
Equity ratio
80.2%
Goodwill
$196.2M
Plus intangible assets of $213.84M
Net debt
−$917.74M
More cash than debt

Total assets and equity ratio

How large the balance sheet of BioMarin Pharmaceutical Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$463.44M$32.92M$21.26M25.4%−$58.12M
2007$815.28M$30.86M$21.26M23.0%−$81.91M
2008$906.7M$28.89M$21.26M30.5%$78.77M
2009$917.16M$64.7M$23.72M35.1%$196.41M
2010$1.26B$157.01M$53.36M56.8%$103.41M
2011$1.31B$231.82M$51.54M59.2%$153.24M
2012$1.57B$214.52M$51.54M64.8%−$102.51M
2013$2.24B$217.41M$54.26M59.8%−$129.16M
2014$2.48B$210.84M$54.26M61.7%−$302.29M
2015$3.73B$881.04M$197.04M64.4%$69.67M
2016$4.02B$750.82M$197.04M68.7%−$106.44M
2017$4.63B$714.55M$197.04M60.6%−$221.5M
2018$4.43B$688.85M$197.04M67.0%−$253.89M
2019$4.69B$653.62M$197.04M66.6%$105.01M
2020$5.85B$613.47M$196.2M70.2%$21.51M
2021$6B$584.85M$196.2M71.0%$75.67M
2022$6.38B$534.77M$196.2M72.2%−$198.14M
2023$6.84B$490.9M$196.2M72.4%$21.94M
2024$6.99B$451.48M$196.2M81.0%−$488.24M
2025$7.59B$410.04M$196.2M80.2%−$917.74M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$288.85M$117.8M$230.73M1.96
2007$585.59M$187.73M$503.68M2.68
2008$559.79M$276.68M$638.57M2.31
2009$300.68M$322.19M$497.08M1.54
2010$274.11M$717.26M$377.52M0.53
2011$195.09M$773.05M$348.33M0.45
2012$450.74M$1.02B$348.22M0.34
2013$784.72M$1.34B$655.57M0.49
2014$945.19M$1.53B$642.9M0.42
2015$592.62M$2.4B$662.29M0.28
2016$789.68M$2.77B$683.24M0.25
2017$1.4B$2.81B$1.17B0.42
2018$1.08B$2.97B$830.42M0.28
2019$753.81M$3.12B$858.82M0.28
2020$1.07B$4.11B$1.09B0.26
2021$1.01B$4.27B$1.09B0.26
2022$1.29B$4.6B$1.09B0.24
2023$1.07B$4.95B$1.1B0.22
2024$1.14B$5.66B$649.47M0.11
2025$1.56B$6.09B$642.87M0.11

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak since 13 Nov 2026, previously Neutral
  • Valuation signal Fairly valued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy